D-1575-2020 Class I Terminated
FDA drug recall D-1575-2020 was initiated by Mylan Institutional LLC on August 17, 2020 and is designated Class I. Reason for recall: Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contai… The recall status is terminated (terminated December 28, 2022). Affected quantity: 13,682 cartons.
Recall Details
- Product Type
- Drugs
- Report Date
- September 9, 2020
- Initiation Date
- August 17, 2020
- Termination Date
- December 28, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,682 cartons
Product Description
Amiodarone Hydrochloride Injection, USP, 450 mg/9 mL (50 mg/mL), 9 mL Single-Dose Vial (NDC 67457-153-99); 10 x 9 mL Single-Dose Vials per carton (NDC 67457-153-09), Rx only, Manufactured by: Mylan Institutional, Galway, Ireland; Manufactured for: Mylan Institutional LLC, Rockford, IL 61103.
Reason for Recall
Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.
Distribution Pattern
Nationwide
Code Information
Lot #: 191207, 191221, 191223 Exp. 11/2021; 200120 Exp. 12/2021